OR WAIT 15 SECS
Swedish based company, SenzaGen, has signed a license agreement with contract research organization (CRO) MB Research Labs.
Swedish based company, SenzaGen, has signed a license agreement with contract research organization (CRO) MB Research Labs, increasing its presence within the United States, it was announced in a Mar. 7, 2019 press release.
Under the terms of the agreement, MB Research Labs will gain the right to market and sell SenzaGen’s animal-free GARD test platform globally. The GARD product portfolio comprises a set of allergy tests that can be performed on human cells in vitro and then utilized in combination with artificial intelligence to replace animal testing in various industries, including pharma.
“I am very happy to sign an agreement with another CRO and with such a strong player as MB Research Labs. By adding an additional CRO to our sales channels in the US, we have now given more end customers access to our innovative tests. In addition, with a driven and respected partner, we are increasing the possibilities of accelerating a change throughout the toxicological testing industry,” said Anki Malmborg Hager, CEO of SenzaGen.
“As a provider of in vitro toxicity testing to the US and worldwide, we always want to use the latest predictive and innovative methods to provide the best in vitro toxicology solutions to our customers. GARD delivers all this, and we look forward to a fruitful collaboration,” added George DeGeorge, PhD DABT, chief scientific officer at MB Research Labs.